NCT04939090 2026-03-04
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06995508 2026-02-17
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT06200181 2026-02-13
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT07403370 2026-02-11
Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis
Shandong Cancer Hospital and Institute
Recruiting
NCT05705492 2026-01-21
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT03118986 2025-10-08
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
The Hospital for Sick Children
Phase 2 Recruiting
NCT03367572 2025-09-25
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Phase 3 Completed
NCT06175273 2025-09-18
POINT
University of Kentucky
Phase 2/3 Completed
NCT07035821 2025-06-25
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy
Shanghai Children's Medical Center
Phase 3 Not yet recruiting
NCT04503668 2025-06-18
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center
Phase 3 Terminated
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed